Top News-TriApex

Home

CRO Services

Disease Models and Pharmacodynamics

Ophthalmic Disease

CNS Disease

Metabolic Disease

CVD and Other Disease

Regulatory Strategies and Safety Assessment

Regulatory Strategy

Drug Metabolism and Pharmacokinetics

Drug Safety Assessment

Safety Assessment of Medical Devices

Clinical Trials and
Laboratory Services

Clinical Trials

Laboratory Services

Technical platform and instrument Bioanalysis Biomarker Clinical and Molecular Pathology Laboratory

TriApex Vision

Innovative CRO enabling new drug R&D in disease-oriented fields

Disease-Oriented R&D

Ophthalmology

In vivo Ocular Disease Models

Ocular Routes of Administration

Clinical Ophthalmology Examinations

Bioanalysis of Eye Tissues

Ophthalmology Pathology Evaluation

Clinical Service

CNS

Disease Models

Drug Safety Assessment

Clinical Research Services

Clinical Research Services

Project Experience

Innovation

iPSCs & Organoids Evaluation Department

Cell Biology & Immunology Evaluation Department

TriApex Empowered

To build an international drug evaluation platform for ophthalmic /CNS/ metabolic disease

News&Insight

Top News Latest Industry News Thoughts and Insights Important Events Video Class Document / Manual Q&A

TriApex Vision

Witness the development of industry innovation, share TriApex exclusive insights

Investor

Announcement Corporate Governance Promotional Materials Investor Contact

TriApex Vision

Building a CRO "bioeconomy" industry ecosystem that meets international standards and is domestically first-class

About us

TriApex Profile Credibility Qualification Social Responsibility Join us

鼎泰愿景

Dedicated to scientific assessment, enabling transformation of innovation, and improving quality of life

Global

En Cn